IMEPITOIN

Possibly Marketed Outside US

Details

Stereochemistry	ACHIRAL
Molecular Formula	C13H14ClN3O2
Molecular Weight	279.722
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

ClC1=CC=C(C=C1)N2CC(=NC2=O)N3CCOCC3

InChI

InChIKey=IQHYCZKIFIHTAI-UHFFFAOYSA-N

InChI=1S/C13H14ClN3O2/c14-10-1-3-11(4-2-10)17-9-12(15-13(17)18)16-5-7-19-8-6-16/h1-4H,5-9H2

HIDE SMILES / InChI

Description
Sources: https://ec.europa.eu/health/documents/community-register/2013/20130225125304/anx_125304_en.pdf
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24357084

Imepitoin (AWD 131–138 or ELB 138; 1-(4-chlorophenyl)-4-morpholino-imidazolin-2-one) is a new anti-epileptic drug recently approved in the European Union for the treatment of canine idiopathic epilepsy. It was developed from a series of imidazolinones due to its pronounced ant seizure activity in a large variety of rodent models of epileptic seizures, combined with a high tolerability in these models. Imepitoin is a centrally acting antiepileptic substance, which crosses the blood brain barrier without involvement of active transport or active clearance, resulting in immediate equilibrium between plasma and brain. Imepitoin acts as low-affinity partial agonists at the benzodiazepine (BZD) site of the GABAA receptor. Hopefully, that the favorable profile of imepitoin for the treatment of epilepsy in dogs will reactivate the interest in partial BZD site agonists as new treatments for human epilepsy.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
GABAA receptor 2 Target ID: GABAA receptor Sources: https://www.ncbi.nlm.nih.gov/pubmed/24357084	Agonist 2678

Conditions

Condition	Modality	Targets	Highest Phase	Product
Idiopathic epilepsy 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25079881	Palliative		Approved 8429	Imepitoin Approved Use For the reduction of the frequency of generalised seizures due to idiopathic epilepsy in dogs for use after careful evaluation of alternative treatment options.

PubMed

Title	Date	PubMed
Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures.	2004 Oct	15461677

Patents

Sample Use Guides

In Vivo Use Guide

for dog: Oral administration at a dose range of 10 mg to 30 mg imepitoin per kg body weight twice daily, approximately 12 hours apart. Each tablet can be halved for appropriate dosing according to the individual body weight of the dog. The required dose will vary between dogs and will depend on the severity of the disorder. The recommended initial dose of imepitoin is 10 mg per kg body weight twice daily. Initiate therapy using the bodyweight in kg and the dosing table. If seizures are not adequatey reduced following a minimum of 1 week of treatment at the current dose the supervising veterinary surgeon should re-assess the dog. Assuming that the veterinary medicinal product is well tolerated by the dog, the dose can be increased by 50 to 100% increments up to a maximum dosage of 30 mg per kg administered twice daily.

Route of Administration: Oral

In Vitro Use Guide

Unknown

Name

Type

Language

IMEPITOIN

Official Name

English

IMEPITION

Common Name

English

IMEPITOIN [EMA EPAR VETERINARY]

Common Name

English

1-(4-CHLOROPHENYL)-4-(MORPHOLIN-4-YL)-1,5-DIHYDRO-2H-IMIDAZOL-2-ONE

Systematic Name

English

PEXION

Brand Name

English

IMEPITOIN [MI]

Common Name

English

imepitoin [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C264